Albert Pares

Summary

Affiliation: University of Barcelona
Country: Spain

Publications

  1. ncbi Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial
    A Pares
    Hospital Clinic i Provincial, University of Barcelona, Spain
    J Hepatol 28:615-21. 1998
  2. ncbi [Physiopathological bases for the treatment of acute alcoholic hepatitis]
    A Pares
    Unidad de Hepatologia, Institut de Malalties Digestives i Metaboliques, Hospital Clinic, IDIBAPS, Barcelona, Espana
    Gastroenterol Hepatol 27:30-9. 2004
  3. ncbi Natural history of primary biliary cirrhosis
    Albert Pares
    Liver Unit, Institute of Digestive Diseases, Hospital Clinic, University of Barcelona, C Villarroel 170, 08036 Barcelona, Spain
    Clin Liver Dis 7:779-94. 2003
  4. ncbi [Liver-assist non-biological artificial systems]
    A Pares
    Unidad de Hepatologia, Institut de Malalties Digestives, Hospital Clinic, Barcelona
    Gastroenterol Hepatol 25:43-7. 2002
  5. ncbi Collagen type Ialpha1 and vitamin D receptor gene polymorphisms and bone mass in primary biliary cirrhosis
    A Pares
    Liver and Metabolic Bone Diseases Units, Department of Rheumatology, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, University of Barcelona, Barcelona, Spain
    Hepatology 33:554-60. 2001
  6. ncbi [Prevalence and factors associated to the presence of fatty liver in apparently healthy adult men]
    A Pares
    Unidade de Alcohología, Hospital Clinic, Universidad de Barcelona
    Med Clin (Barc) 114:561-5. 2000
  7. ncbi Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver
    A Pares
    Liver Unit, Hospital Clinic, University of Barcelona, Spain
    J Hepatol 32:561-6. 2000
  8. ncbi The effect of the alendronate on OPG/RANKL system in differentiated primary human osteoblasts
    Anna Enjuanes
    Metabolic Bone Diseases Unit, Department of Rheumatology, Hospital Clinic IDIBAPS, University of Barcelona, Barcelona, Spain
    Endocrine 37:180-6. 2010
  9. ncbi Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis
    Nuria Guanabens
    Metabolic Bone Diseases Unit, Hospital Clinic, Institut d Investigacions Mèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain
    Am J Gastroenterol 98:2268-74. 2003
  10. ncbi Low bone mass and severity of cholestasis affect fracture risk in patients with primary biliary cirrhosis
    Nuria Guanabens
    Metabolic Bone Diseases Unit, Service of Rheumatology, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
    Gastroenterology 138:2348-56. 2010

Detail Information

Publications27

  1. ncbi Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial
    A Pares
    Hospital Clinic i Provincial, University of Barcelona, Spain
    J Hepatol 28:615-21. 1998
    ..Therefore, this study was carried out to determine the effect of silymarin in alcoholics with liver cirrhosis with respect to survival and clinical and laboratory changes...
  2. ncbi [Physiopathological bases for the treatment of acute alcoholic hepatitis]
    A Pares
    Unidad de Hepatologia, Institut de Malalties Digestives i Metaboliques, Hospital Clinic, IDIBAPS, Barcelona, Espana
    Gastroenterol Hepatol 27:30-9. 2004
  3. ncbi Natural history of primary biliary cirrhosis
    Albert Pares
    Liver Unit, Institute of Digestive Diseases, Hospital Clinic, University of Barcelona, C Villarroel 170, 08036 Barcelona, Spain
    Clin Liver Dis 7:779-94. 2003
    ..Prognostic models based on serial measurements of the independent predictors of poor prognosis would lead to a more accurate prediction of survival; however, they probably will not replace clinical outlook...
  4. ncbi [Liver-assist non-biological artificial systems]
    A Pares
    Unidad de Hepatologia, Institut de Malalties Digestives, Hospital Clinic, Barcelona
    Gastroenterol Hepatol 25:43-7. 2002
  5. ncbi Collagen type Ialpha1 and vitamin D receptor gene polymorphisms and bone mass in primary biliary cirrhosis
    A Pares
    Liver and Metabolic Bone Diseases Units, Department of Rheumatology, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, University of Barcelona, Barcelona, Spain
    Hepatology 33:554-60. 2001
    ..In conclusion, the COLIA1 but not VDR polymorphism is a genetic marker of peak bone mass in patients with PBC, although the severity of cholestasis is the main factor for osteoporosis since it is associated with the rate of bone loss...
  6. ncbi [Prevalence and factors associated to the presence of fatty liver in apparently healthy adult men]
    A Pares
    Unidade de Alcohología, Hospital Clinic, Universidad de Barcelona
    Med Clin (Barc) 114:561-5. 2000
    ..Therefore the aim of this study was to assess the prevalence and associated factors for fatty liver diagnosed by ultrasonography...
  7. ncbi Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver
    A Pares
    Liver Unit, Hospital Clinic, University of Barcelona, Spain
    J Hepatol 32:561-6. 2000
    ..The aim of this study was to assess the efficacy of ursodeoxycholic acid (UDCA) for primary biliary cirrhosis in a randomized, double-blind placebo-controlled trial...
  8. ncbi The effect of the alendronate on OPG/RANKL system in differentiated primary human osteoblasts
    Anna Enjuanes
    Metabolic Bone Diseases Unit, Department of Rheumatology, Hospital Clinic IDIBAPS, University of Barcelona, Barcelona, Spain
    Endocrine 37:180-6. 2010
    ..Thus, we conclude that alendronate does not affect the ALP activity and OPG gene expression in differentiated hOB, but may increase RANKL gene expression induced by vitamin D...
  9. ncbi Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis
    Nuria Guanabens
    Metabolic Bone Diseases Unit, Hospital Clinic, Institut d Investigacions Mèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain
    Am J Gastroenterol 98:2268-74. 2003
    ..In this study, we have compared two bisphosphonates, alendronate and cyclical etidronate, that inhibit osteoclast-mediated bone resorption and have examined their effects on bone mass in patients with this disease...
  10. ncbi Low bone mass and severity of cholestasis affect fracture risk in patients with primary biliary cirrhosis
    Nuria Guanabens
    Metabolic Bone Diseases Unit, Service of Rheumatology, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
    Gastroenterology 138:2348-56. 2010
    ..We studied a large series of women with PBC to assess the prevalence and risk factors for fractures and the fracture threshold...
  11. ncbi Effects of bilirubin and sera from jaundiced patients on osteoblasts: contribution to the development of osteoporosis in liver diseases
    Silvia Ruiz-Gaspa
    Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas CIBEREHD, Institut d Investigacions Biome diques August Pi i Sunyer, University of Barcelona, Barcelona, Spain
    Hepatology 54:2104-13. 2011
    ..These results support the deleterious consequences of increased bilirubin in advanced chronic cholestasis and in end-stage liver diseases, resulting in disturbed bone formation related to osteoblast dysfunction...
  12. ncbi [Osteoporosis in liver cirrhosis]
    Nuria Guanabens
    Servicio de Reumatologia, Unidad de Hepatologia, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Insititut d Investigacions Biomèdiques August Pi i Sunyer, Hospital Clinic, Universidad de Barcelona, Espana
    Gastroenterol Hepatol 35:411-20. 2012
    ..There are no specific recommendations on drug treatment but bisphosphonates are effective in increasing bone mass in patients with chronic cholestasis and have a good safety profile...
  13. ncbi Extracorporeal albumin dialysis: a procedure for prolonged relief of intractable pruritus in patients with primary biliary cirrhosis
    Albert Pares
    Liver Unit, Institut Clinic de Malalties Digestives, Hospital Clinic, Barcelona, Spain
    Am J Gastroenterol 99:1105-10. 2004
    ....
  14. ncbi Severity of cholestasis and advanced histological stage but not menopausal status are the major risk factors for osteoporosis in primary biliary cirrhosis
    Nuria Guanabens
    Metabolic Bone Diseases Unit, Service of Rheumatology, Hospital Clinic, IDIBAPS, University of Barcelona, C Villarroel 170, 08036 Barcelona, Spain
    J Hepatol 42:573-7. 2005
    ..Since primary biliary cirrhosis (PBC) is usually diagnosed in postmenopausal women with minor cholestasis, it has been questioned whether PBC itself represents a further risk for osteoporosis...
  15. ncbi The effect of the alendronate on OPG/RANKL system in differentiated primary human osteoblasts
    Anna Enjuanes
    Metabolic Bone Diseases Unit, Department of Rheumatology, Hospital Clinic IDIBAPS, University of Barcelona, Barcelona, Spain
    Endocrine 37:322-8. 2010
    ..Thus, we conclude that alendronate does not affect the ALP activity and OPG gene expression in differentiated hOB, but may increase RANKL gene expression induced by vitamin D...
  16. ncbi High osteoprotegerin serum levels in primary biliary cirrhosis are associated with disease severity but not with the mRNA gene expression in liver tissue
    Nuria Guanabens
    Metabolic Bone Diseases Unit, Hospital Clinic, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, IDIBAPS, University of Barcelona, Barcelona, Spain
    J Bone Miner Metab 27:347-54. 2009
    ..In conclusion, osteoprotegerin and RANKL are abnormal in patients with PBC, regardless of osteoporosis. The elevated circulating osteoprotegerin is associated with the severity of disease, but not with gene expression in the liver...
  17. ncbi Treatment of resistant pruritus from cholestasis with albumin dialysis: combined analysis of patients from three centers
    Albert Pares
    Liver Unit, Hospital Clinic, IDIBAPS, CIBERehd, University of Barcelona, Barcelona, Spain
    J Hepatol 53:307-12. 2010
    ..Therefore, we analyzed patients with resistant pruritus treated with MARS from three centers, to assess the changes on pruritus and the indices of cholestasis...
  18. ncbi Treatment of bone disorders in liver disease
    Albert Pares
    Liver Unit, Digestive Diseases Institute and Metabolic Bone Diseases Unit, Department of Rheumatology Hospital Clínic, IDIBAPS, Barcelona, Spain
    J Hepatol 45:445-53. 2006
  19. ncbi Management of osteoporosis in liver disease
    Nuria Guanabens
    Liver Unit, Department of Rheumatology, Hospital Clinic, CIBERHED, University of Barcelona, Barcelona, Spain
    Clin Res Hepatol Gastroenterol 35:438-45. 2011
    ..Randomized studies assessing bisphosphonates in larger series of patients, the development of new drugs for osteoporosis and the improvement in the management of liver transplant recipients may change the future...
  20. ncbi Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid
    Albert Pares
    Liver Unit, Digestive Diseases Institute, Hospital Clinic, IDIBAPS, Barcelona, Spain
    Gastroenterology 130:715-20. 2006
    ....
  21. ncbi Incidence, risk factors, and survival of hepatocellular carcinoma in primary biliary cirrhosis: comparative analysis from two centers
    Anna Cavazza
    Liver Unit, Digestive Diseases Institute, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Hospital Clinic, IDIBAPS, Barcelona, Spain
    Hepatology 50:1162-8. 2009
    ..The slight disparities observed between the two series might be explained by patient features on diagnosis of liver disease...
  22. ncbi Serum immunological profile in patients with chronic autoimmune cholestasis
    Manuel Romero-Gomez
    Unidad de Hepatologia, Hospital Universitario de Valme, Sevilla, Spain
    Am J Gastroenterol 99:2150-7. 2004
    ..To compare patients who had biochemical and histological features of chronic autoimmune cholestasis (CAIC) using serological autoantibody profiling...
  23. ncbi Osteoporosis in primary biliary cirrhosis: pathogenesis and treatment
    Albert Pares
    Liver Unit, Institute of Digestive Diseases, Hospital Clinic, Institut d Investigacions Biomèdiques August Pi Sunyer, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Barcelona, Spain
    Clin Liver Dis 12:407-24; x. 2008
    ..The potential usefulness of new agents requires further evaluation...
  24. ncbi Gene polymorphisms as predictors of decreased bone mineral density and osteoporosis in primary biliary cirrhosis
    Albert Pares
    Liver Unit, Hospital Clinic, University of Barcelona, Spain
    Eur J Gastroenterol Hepatol 17:311-5. 2005
    ..These features may exceed the potential effect of gene polymorphisms on osteoporosis in PBC...
  25. ncbi Liver and bone
    Nuria Guanabens
    Department of Rheumatology, University of Barcelona, Barcelona, Spain
    Arch Biochem Biophys 503:84-94. 2010
    ..Randomized studies assessing bisphosphonates in larger series of patients, the development of new drugs for osteoporosis and the improvement in the management of liver transplant recipients may change the future...
  26. ncbi Albumin dialysis improves hepatic encephalopathy and decreases circulating phenolic aromatic amino acids in patients with alcoholic hepatitis and severe liver failure
    Albert Pares
    Liver Unit, Digestive Diseases Institute, Hospital Clinic, Centro de Investigaciones Biomédicas en Red de Enfermedades Hepáticas y Digestivas, Institut d Investigacions Biomediques August Pi i Sunyer, Barcelona, Spain
    Crit Care 13:R8. 2009
    ..The aim of this study was to assess the effects of albumin dialysis on hepatic encephalopathy and circulating levels of amino acids in severe alcoholic hepatitis...
  27. ncbi [Natural history of primary biliary cirrhosis]
    Albert Pares
    Unidad de Hepatologia, Institut Clinic de Malalties Digestives i Metaboliques, Hospital Clinic, IDIBAPS, Barcelona, Espana
    Gastroenterol Hepatol 31:500-7. 2008
    ..There are distinct mathematical prognostic models that sensitively predict the probability of survival and are useful to determine disease severity in specific patients...